This was a recent article which was posted on the DrugResearcher.com website, by Emilie Reymond, on March 8, 2007. In it, she discusses the recent Acquisition of a Chinese firm by Frontier Biosciences, a US services provider.
US services provider Frontier Biosciences has announced that it has bought a majority stake in a China-based preclinical contract research organisation (CRO).
With this new deal, Frontier becomes a shareholder and partner in the National Chengdu Center for Safety Evaluation of Drugs (NCCSED) - a contract research lab specialised in drug safety evaluation.
The move is designed to enable the firm to boost its preclinical capacity in the country.
Significantly reduced costs, shorter duration of the studies, and the possibility of simultaneous approval in multiple markets are just some of the major benefits of doing trials in China, which have contributed to the country's appeal and more drug makers are outsourcing more and more clinical and preclinical work to China-based CROs.
Furthermore, animal welfare group PETA recently alleged that a number of pharma companies are exporting their animal testing to countries with no or poor animal welfare standards to avoid US laws.
Recent legal reform, raised manufacturing standards and reduced bureaucracy have made the region highly attractive to its western counterparts, who are always looking to cut costs without sacrificing quality of work.
The new facility Frontier is currently building is expected to be up and running by early 2008.
To view the entire article at its original location click on the title of this post.
AdMark China is committed to finding for our clients the best possible talent as quickly as possible. Contact us at info@admark china.com or at +86 21 6288 9292.